# A Phase I Study for Safety and Tolerability of AL002.

> **NCT03635047** · PHASE1 · COMPLETED · sponsor: **Alector Inc.** · enrollment: 69 (actual)

## Conditions studied

- Healthy
- Alzheimer Disease

## Interventions

- **BIOLOGICAL:** AL002
- **OTHER:** Saline Solution

## Key facts

- **NCT ID:** NCT03635047
- **Lead sponsor:** Alector Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-12
- **Primary completion:** 2020-08-03
- **Final completion:** 2020-11-25
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03635047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03635047, "A Phase I Study for Safety and Tolerability of AL002.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03635047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*